Repotrectinib in <i>ROS1</i> Fusion–Positive Non–Small-Cell Lung Cancer

Abstract

Repotrectinib had durable clinical activity in patients with <i>ROS1</i> fusion-positive NSCLC, regardless of whether they had previously received a ROS1 TKI. Adverse events were mainly of low grade and compatible with long-term administration. (Funded by Turning Point Therapeutics, a wholly owned subsidiary of Bristol Myers Squibb; TRIDENT-1 ClinicalTrials.gov number, NCT03093116.).